WATERTOWN, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced that data from its Phase 1 clinical trial evaluating MYB RNA degrader, REM-422, in patients with recurrent or metastatic (R/M) adenoid cystic carcinoma (ACC), has been accepted for a late-breaking oral presentation in the Clinical Trials Plenary Session at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place on October 22-26 at the Hynes Convention Center in Boston.

The presentation will highlight results from the ongoing Phase I trial’s primary objectives of defining safety, dose-limiting toxicities, and a recommended phase 2 dose (RP2D). Secondary objectives include evaluating preliminary antitumor activity and pharmacokinetics of REM-422 in patients with R/M ACC.

Oral Presentation Details:

• Title: A Phase I Trial of the MYB RNA degrader REM-422 in patients with recurrent or metastatic (R/M) adenoid cystic carcinoma (ACC)
• Presenter: Glenn J. Hanna, MD, Dana-Farber Cancer Institute
• Date & Time: Friday, October 24
  Plenary Session 4: Clinical Trials Plenary Session 10:00 -11:40 am
• Location: Level 3, Ballroom AB
  

Poster Presentation Details:

• Title: A phase I trial of the MYB RNA degrader REM-422 in patients with recurrent or metastatic (R/M) adenoid cystic carcinoma (ACC)
• Presenter: Glenn Hanna, MD, Dana-Farber Cancer Institute
• Session and Poster Number: Poster Session B, LB-B005
• Date and Time: Friday, October 24, 12:30-4pm
• Location: Level 2, Exhibit Hall D
  

Additionally, Remix Therapeutics will be taking part in a session on targeting RNA with small molecules.

Session Details:

• Title: Concurrent Session 9: Targeting RNA with Small Molecules
• Co-Chair: Chris Bowden, MD, Chief Medical Officer, Remix Therapeutics
• Presenter: Charles Kung, PhD, Vice President of Biology, Remix Therapeutics
• Title: REM-422, a first-in-class mRNA degrader of the MYB oncogene
• Date & Time: Saturday, October 25, 4:15 – 5:55 pm
• Location: Level C, Ballroom 3

About REM-422
REM-422 is a first/best-in-class, potent, selective, and oral small molecule mRNA degrader that induces the reduction of MYB mRNA and subsequent protein expression. REM-422 functions by facilitating the incorporation of poison exons in the MYB mRNA transcript, leading to nonsense-mediated decay of the transcript. REM-422 is currently in Phase 1 clinical studies in both ACC and Acute Myeloid Leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS). REM-422 was granted Orphan Drug Designation by the U.S Food and Drug Administration for ACC and AML.

About Remix Therapeutics
Remix Therapeutics is a clinical-stage biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and address disease drivers at their origin. Remix's REMaster™ technology platform leverages cutting-edge data science, biomolecular sciences and chemistry approaches to identify orally administered compounds that modulate gene expression. Remix's innovative therapeutic approach led to the discovery of REM-422, a first-in-class RNA processing modulator in oncology, now being evaluated in Phase 1 clinical studies to treat acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (HR-MDS) and adenoid cystic carcinoma (ACC). For more information visit www.remixtx.com.

Contacts:

Media Contact:
Lisa Buffington
Buffington Comms
lbuffington@remixtx.com

Investor Contact:
Will O'Connor  
Precision AQ
Will.OConnor@precisionaq.com